Nonprofit sues to block licensing of patents to Gilead

Nonprofit group Knowledge Ecology International (KEI) said it filed a lawsuit against the National Institutes of Health (NIH) “to block or invalidate an exclusive license of patents on a new chimeric antigen receptor T-cell (CAR T) therapy to Gilead Sciences.”

KEI is suing to challenge the National Institutes of Health’s plan to grant a license on taxpayer-funded cancer treatment technology to Gilead Sciences, arguing that the decision ignores the public’s interest in affordable drugs.

KEI said the license in question “involves a set of patent applications regarding the development of a CD30 chimeric antigen receptor (CAR)-based immunotherapy using autologous (meaning one individual is both the donor and the recipient) T-cells” for the treatment of:

  • Hodgkin lymphoma (HL),
  • Non-Hodgkin’s Lymphoma (NHL),
  • diffuse large B cell lymphoma (DLBCL),
  • peripheral T cell lymphoma not otherwise specified (PTCL–NOS),
  • anaplastic large cell lymphoma (ALCL), and
  • angioimmunoblastic T cell lymphoma (AITL)